A new study suggests that Takeda Pharmaceuticals' diabetes drug Actos holds as much risk to patient health as does GlaxoSmithKline Plc's (NYSE:GSK) heavily criticized Avandia.
Over 36,000 diabetes patients using one of the drugs took part in the study, and researchers found that 602 Avandia patients suffered from a heart attack, heart failure, or died, and 599 patients taking Actos suffered the same outcomes; 217 patients reportedly died from each drug group.
SmarTrend is bullish on shares of GlaxoSmithKline and our subscribers were alerted to buy on July 14, 2010 at $36.15. The stock has risen 3.3% since the alert was issued.
GlaxoSmithKline is currently above its 50-day moving average (MA) of $36.00 and should find resistance at its 200-day MA of $38.14.
In the last five trading sessions, the 50-day MA has climbed 0.91% while the 200-day MA has slid 0.2%.
Over 36,000 diabetes patients using one of the drugs took part in the study, and researchers found that 602 Avandia patients suffered from a heart attack, heart failure, or died, and 599 patients taking Actos suffered the same outcomes; 217 patients reportedly died from each drug group.
SmarTrend is bullish on shares of GlaxoSmithKline and our subscribers were alerted to buy on July 14, 2010 at $36.15. The stock has risen 3.3% since the alert was issued.
GlaxoSmithKline is currently above its 50-day moving average (MA) of $36.00 and should find resistance at its 200-day MA of $38.14.
In the last five trading sessions, the 50-day MA has climbed 0.91% while the 200-day MA has slid 0.2%.
No comments:
Post a Comment